Literature DB >> 19740321

Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas.

Camilla Rydberg1, Anne Månsson, Rolf Uddman, Kristian Riesbeck, Lars-Olaf Cardell.   

Abstract

Toll-like receptors (TLRs) are increasingly implicated in the pathogenesis of cancer. The present study describes TLR expression and function in healthy and malignant airway epithelial cells. The squamous cell carcinoma cell line Detroit-562 was compared with the healthy bronchial epithelial cell line NL-20 and primary human nasal epithelial cells (HNECs). TLR2, TLR3 and TLR5 were present in primary head and neck squamous cell carcinomas (HNSCCs). Consistent with this, Detroit-562 expressed TLR2, TLR3 and TLR5, whereas NL-20 expressed mainly TLR3 and HNECs expressed TLR2-5. In Detroit-562, Pam(3)CSK(4), poly(I:C) and flagellin, ligands for TLR2, TLR3 and TLR5, respectively, induced an up-regulation of intercellular adhesion molecule 1 (ICAM-1), an increase in interleukin (IL)-6 and IL-8 secretion and a decrease in cell viability. Additionally, poly(I:C) affected IL-1beta production and the migratory behaviour of Detroit-562. NL-20 responded with a slight increase in IL-8 secretion upon poly(I:C) stimulation. Poly(I:C) induced a small increase in IL-1beta, IL-6 and IL-8 production in HNECs, while Pam(3)CSK(4) increased viability. The TLR signalling was transcription-dependent, but the pathways involved differed among TLRs as well as cells. In Detroit-562, TLR2 and TLR5 activation was mediated via c-jun N-terminal kinase (JNK)-, p38-, phosphatidylinositol 3-kinase (PI3K)- and nuclear factor (NF)-kappaB-related pathways, while TLR3 was dependent on NF-kappaB. In NL-20, TLR3 signalled via p38, and in HNECs, NF-kappaB, JNK and extracellular signal-regulated kinase (ERK) appeared to be involved. We found that TLR agonists induced a robust response in HNSCCs, characterized by generation of inflammation and cell death. A similar response was not seen in normal epithelial cells. Thus, the TLR system should be considered an important target in future antitumour immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19740321      PMCID: PMC2753959          DOI: 10.1111/j.1365-2567.2008.03041.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

Review 1.  Recognition of pathogen-associated molecular patterns by TLR family.

Authors:  Shizuo Akira; Hiroaki Hemmi
Journal:  Immunol Lett       Date:  2003-01-22       Impact factor: 3.685

Review 2.  Role of cytokines in head and neck squamous cell carcinoma.

Authors:  Ralph Pries; Stefan Nitsch; Barbara Wollenberg
Journal:  Expert Rev Anticancer Ther       Date:  2006-09       Impact factor: 4.512

3.  Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.

Authors:  Carter Van Waes; Angela A Chang; Peter F Lebowitz; Colleen H Druzgal; Zhong Chen; Yusri A Elsayed; John B Sunwoo; Susan F Rudy; John C Morris; James B Mitchell; Kevin Camphausen; David Gius; Julian Adams; Edward A Sausville; Barbara A Conley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-11       Impact factor: 7.038

Review 4.  Transcriptional signaling by double-stranded RNA: role of TLR3.

Authors:  Ganes C Sen; Saumendra N Sarkar
Journal:  Cytokine Growth Factor Rev       Date:  2005-02       Impact factor: 7.638

Review 5.  Cell adhesion molecules in the development and progression of malignant melanoma.

Authors:  J P Johnson
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

6.  Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer.

Authors:  Ralph Pries; Lisa Hogrefe; Lei Xie; Henning Frenzel; Carsten Brocks; Claudia Ditz; Barbara Wollenberg
Journal:  Int J Mol Med       Date:  2008-02       Impact factor: 4.101

Review 7.  Toll-like receptors in the pathogenesis of human disease.

Authors:  Donald N Cook; David S Pisetsky; David A Schwartz
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

Review 8.  Toll-like receptors. II. Distribution and pathways involved in TLR signalling.

Authors:  F Sandor; M Buc
Journal:  Folia Biol (Praha)       Date:  2005       Impact factor: 0.906

9.  Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response.

Authors:  Mirko Ritter; Detlev Mennerich; Andreas Weith; Peter Seither
Journal:  J Inflamm (Lond)       Date:  2005-11-29       Impact factor: 4.981

10.  Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium.

Authors:  Jonathan L Koff; Matt X G Shao; Iris F Ueki; Jay A Nadel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-03-28       Impact factor: 5.464

View more
  24 in total

1.  The proteome of Toll-like receptor 3-stimulated human immortalized fibroblasts: implications for susceptibility to herpes simplex virus encephalitis.

Authors:  Rebeca Pérez de Diego; Claire Mulvey; Mark Crawford; Matthew W B Trotter; Lazaro Lorenzo; Vanessa Sancho-Shimizu; Laurent Abel; Shen-Ying Zhang; Jean-Laurent Casanova; Jasminka Godovac-Zimmermann
Journal:  J Allergy Clin Immunol       Date:  2013-02-21       Impact factor: 10.793

2.  Defective NF-κB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA.

Authors:  Naoki Umemura; Jianzhong Zhu; Yvonne K Mburu; Adriana Forero; Paishiun N Hsieh; Ravikumar Muthuswamy; Pawel Kalinski; Robert L Ferris; Saumendra N Sarkar
Journal:  Cancer Res       Date:  2011-11-04       Impact factor: 12.701

3.  ICAM-1 orchestrates the abscopal effect of tumor radiotherapy.

Authors:  Yang Zhao; Ting Zhang; Yanpu Wang; Dehua Lu; Jinhong Du; Xun Feng; Haoyi Zhou; Ning Liu; Hua Zhu; Shangbin Qin; Chenxin Liu; Xianshu Gao; Zhi Yang; Zhaofei Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

Review 4.  Modulation of Toll-like receptor signaling in innate immunity by natural products.

Authors:  Luxi Chen; Jianhua Yu
Journal:  Int Immunopharmacol       Date:  2016-02-15       Impact factor: 4.932

Review 5.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

6.  Upregulation of ATF3 inhibits expression of the pro-inflammatory cytokine IL-6 during Neisseria gonorrhoeae infection.

Authors:  Christine M Calton; Laura K Wade; Magdalene So
Journal:  Cell Microbiol       Date:  2013-05-23       Impact factor: 3.715

7.  Magnetically attachable stencils and the non-destructive analysis of the contribution made by the underlying matrix to cell migration.

Authors:  William J Ashby; John P Wikswo; Andries Zijlstra
Journal:  Biomaterials       Date:  2012-08-31       Impact factor: 12.479

Review 8.  Roles of Toll-Like Receptor 3 in Human Tumors.

Authors:  Xin Zheng; Song Li; Hui Yang
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

9.  Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue.

Authors:  J H Kauppila; A E Mattila; T J Karttunen; T Salo
Journal:  Br J Cancer       Date:  2013-01-03       Impact factor: 7.640

10.  Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic.

Authors:  Benjamin Vérillaud; Mélanie Gressette; Yannis Morel; Carine Paturel; Philippe Herman; Kwok Wai Lo; Sai Wah Tsao; Michel Wassef; Anne-Sophie Jimenez-Pailhes; Pierre Busson
Journal:  Infect Agent Cancer       Date:  2012-12-03       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.